Clinical trial

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

NCT02799095

Study summary

ClinicalTrials.gov

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention ALKS 4230 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ALKS 4230 + pembrolizumab Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-09-14

PhasePHASE1 / PHASE2

Conditions

Advanced Solid Tumorsunresolved

Interventions

ALKS 4230DRUG

ALKS 4230 + pembrolizumabDRUG

Sponsors & collaborators

Mural Oncology, Inclead sponsor

Mapped research locations

MadridSpain4 SeoulSouth Korea2 New YorkNew York, United States1 BostonMassachusetts, United States1 DallasTexas, United States1 TorontoOntario, Canada1 BarcelonaSpain1 ClevelandOhio, United States1 TampaFlorida, United States1 MontrealQuebec, Canada1 DenverColorado, United States1 DetroitMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02799095 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.